Advances in technologies for immunoassay testing have enabled the development of 15-minute whole-blood assays for cardiac markers in the evaluation of patients with acute coronary syndromes (ACS) and congestive heart failure (CHF). The analytical performance of these assays is equivalent to the testing that is carried out in the central laboratory. Rapid whole-blood point-of-care assays for troponin, creatine kinase isoenzyme CK-MB, myoglobin, and B-type natriuretic peptides have facilitated efforts to restructure conventional approaches to ACS and CHF in the emergency room. The implementation of immunoassay testing has improved the outcomes for ACS and CHF patients, including decreased emergency room and hospital length-of-stay, decreased overall cost and earlier discharge of low-risk patients.
PATHFAST- Point of Care for ACS and CHF
PATHFAST is an easy-to-use, bench-top chemiluminescent immunoassay analyzer providing affordable, core-lab quality results from whole blood samples in under 17 minutes. With the flexibility to run up to six tests simultaneously, and results that are unaffected by hemolysis†, PATHFAST ensures that accurate results are available to the caregiver quickly.
PATHFAST determines the quantity of NTproBNP from both whole blood and plasma samples, providing results within minutes, and facilitating critical care decisions for patients with congestive heart failure and acute coronary syndrome. The result from NTproBNP assay aids in the diagnosis and assessment of the severity of congestive heart failure and risk stratification in patients with acute coronary syndrome.
Pathfast is number 1 in precision among point-of-care analyzers. Consider Pathfast Cardiac Biomarker Analyzer for early detection of ACS and for better quality cardiac care. Call 800-431-2123 or email firstname.lastname@example.org.
Blogger July 20th, 2018
Posted In: Blog, point of care testing
Point of care, point of care for acute coronary syndrome, point of care testing, point of care testing for congestive heart failure